Viridian Therapeutics' Superior Prospects Make It A Buy [Seeking Alpha]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Seeking Alpha
Follow Play 8min Summary Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 achieved significant efficacy in the Thrive trial, meeting all primary and secondary endpoints with strong proptosis and diplopia resolution rates, and was well-tolerated. Financially, Viridian has a market cap of $1.87bn and a cash runway of 9–10 quarters, with a potential annual revenue of $8bn if successful. Despite past data inconsistencies, VRDN is trading at 52-week highs, presenting a derisked buy opportunity with considerable upside potential. J Studios I have been in and out of Viridian Therapeutics, Inc. NASDAQ: VRDN ) starting around 2022, and the going has been good. VRDN has been up considerably since my last article , and they now have some late-stage About the TPT service Thanks for reading. At the Total Pharma Tracker , we off
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn DataBusiness Wire
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.MarketBeat
- Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - Global Forecast to 2030 [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at BTIG Research from $56.00 to $61.00. They now have a "buy" rating on the stock.MarketBeat
VRDN
Earnings
- 11/12/24 - Miss
VRDN
Sec Filings
- 11/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- 10/18/24 - Form SC
- VRDN's page on the SEC website